Objective: In heart failure atrial natriuretic peptide (ANP) release in response to volume expansion is impaired while the renin-angiotensin system is activated. This study was designed to test the hypothesis that ANP release in heart failure is dependent on an activated angiotensin system. Methods: We studied the ANP and renin-angiotensin systems in a rat model of shunt-induced high-output heart failure, in which we rapidly increased circulating fluid volume with a 5 ml, hyperoncotic infusion, and evaluated the effects of acute inhibition of the angiotensin converting enzyme as well as of the blockade of the angiotensin II type 1 receptors on the ANP release and on renal excretory function. Results: ANP and angiotensin II plasma concentrations prior to volume expansion were elevated ( p,0.05) in rats with aortocaval shunt compared to controls. The diuretic response to acute volume expansion (18.561.5 vs. 48.262.4 ml / min, p,0.001) was markedly blunted. ANP release was attenuated in rats with aortocaval shunt, as was the increase of its second messenger cGMP in plasma and urine. The blunted increase in ANP plasma levels was not due to depleted cardiac stores as cardiac ANP content, as well as ANP synthesis, were increased ( p,0.05). Acute inhibition of the angiotensin converting enzyme as well as blockade of the angiotensin II type 1 receptors restored ANP release in response to volume expansion ( p,0.01). Moreover, acute inhibition of the renin-angiotensin system completely normalized the diuretic response. Conclusions: Our data suggest that the ANP system is impaired in rats with aortocaval shunt. The activation of the angiotensin system contributes to the impairment of the ANP system. Acute inhibition of the angiotensin II system significantly improved the ability of the ANP system to respond to acute volume expansion. Our findings indicate a hitherto fore unappreciated interaction between both systems and suggest additional mechanisms for the beneficial effects of angiotensin converting enzyme inhibition or angiotensin II type 1 receptor antagonists in heart failure.
Introduction
tone (for review see [1] [2] [3] [4] [5] ). However, in heart failure ANP responses and actions are sharply curtailed. For instance, in With acute volume expansion, atrial natriuretic peptide dilated cardiomyopathy, the ANP increase with sudden (ANP) release normally evokes a natriuretic and diuretic volume expansion was diminished [6] or absent [7] . In response, as well as a reduced intravascular volume, an heart failure, volume and sodium retention occurred in increased capillary permeability and a diminished vascular spite of an activated ANP system. The cardiac production of ANP is increased in heart failure particularly in the ventricles, which results in elevated plasma levels [8] [9] [10] .
Nevertheless, despite markedly elevated ANP plasma with 9 animals per group for the measurements of ANP levels, volume and electrolyte homeostasis in heart failure tissue content and mRNA-expression. is impaired.
The biological action of ANP is mainly mediated by its 2.2. Shunt Operation second messenger, cyclic guanosine monophosphate (cGMP) [11, 12] , which is formed by the particulate
The aortocaval shunt was induced under ether anesthesia guanylate cyclase of the natriuretic peptide receptors type by a modified method developed by Garcia [23] . Briefly, a A and B [13, 14] . Stimulation of the guanylate cyclase with laparotomy was performed and the aorta was punctured ANP results in elevated cGMP levels in plasma and with a 1.2 mm disposable needle (external diameter, Braun increased urinary cGMP excretion [15] . The cGMP excreMelsungen, Melsungen, Germany) distal to the renal tion correlates well with the ANP-induced natriuresis and arteries. The needle was advanced into the adjacent inferior diuresis. We showed earlier that a dissociation of natvena cava. After temporarily clamping the vessels, the riuresis, diuresis, and cGMP excretion could only be needle was withdrawn and the aortic puncture site was achieved with an ANP analog [16] .
sealed with a drop of cyanoacrylate glue (Instant Krazy In heart failure, other regulatory systems, notably the Glue, Borden Company, Willowdale, Ontario, Canada). renin-angiotensin system, are activated simultaneously. It
Perioperative mortality was less than 3%. Sham-operated has been shown previously by several groups that ANP control animals were treated identically, except that no inhibits the renin-angiotensin-aldosterone system by inpuncture of the vessels was performed. hibiting renin release [17] and decreasing aldosterone production [18] . This ANP-mediated effect might be of 2.3. Acute volume expansion particular importance in heart failure [19] . However, the angiotensin (Ang) II system remains activated in heart An acute volume expansion was performed in anesfailure in spite of elevated ANP plasma levels which might thetized rats (chloralhydrate 400 mg / kg) 30 days after be an indication for the decreased efficacy of natriuretic shunt production. For measurements of diuresis and peptides in heart failure. We investigated whether or not cGMP-excretion, a PE-50 polyethylene catheter was inAng II modulates the release of ANP and influences its serted into the bladder and urine was collected in 20 min ability to induce diuretic responses in heart failure. To periods. Sodium chloride (0.9%) was infused at a flow rate induce heart failure, we relied on the aortocaval shunt, an of 1.5 ml / h throughout the whole experiment. As illusestablished model of moderate high-output heart failure trated in Fig. 1 , surgery was followed by a 20 min [20] [21] [22] . To achieve more insight into mechanisms, we equilibration period before baseline values were obtained analyzed the atrial and ventricular ANP-mRNA expresduring the following 20 min. Acute volume expansion was sion, the cardiac ANP protein content, the ANP release then performed with 5 ml of hyperoncotic solution (HAES after an acute volume expansion and the renal responses 10%, Braun Melsungen, Melsungen, Germany) infused after inhibition of the renin-angiotensin system with either within 5 min. Urine for this period (t1) was collected an angiotensin converting enzyme inhibitor (ACEI) or an during the 5 min of infusion of hyperoncotic solution and angiotensin II receptor type 1 (AT1) antagonist.
during the following 15 min. The experiment was continued for two additional collection periods of 20 min each (t2 and t3). Urine volume was collected for the entire 20 min periods for measurements of diuresis and cGMP 2. Methods excretion. Hemodynamic values were analyzed at the end of each period and in addition at the end of the acute 2.1. Animals volume expansion.
Male Wistar rats (230-250 g) from Moellegaard Animal 2.4. Determination of C-and N-terminal ANP, cGMP, Farms (Schoenwalde, Germany) were fed normal rat chow and Angiotensin II (Ang II) and allowed free access to tap water. The animals were kept on a 12-h light-dark cycle. All experiments were Blood samples for ANP (800 ml) were withdrawn from performed between 7 and 12 a.m. The studies were the carotid artery at the end of each observation period in approved and performed according to Guide for the Care Na-EDTA preloaded (final concentration 7 mM) and and Use of Laboratory Animals published by the US prechilled tubes. Degradation of ANP was prevented with National Institute of Health (NIH Publication No. 85-23, phenyl-methyl-sulfonyl fluoride (final concentration 10 revised 1996). A first set of experiments was performed mM) and pepstatin (3 mM). The blood was centrifuged at with 8-12 animals per group (12 controls, 8-9 in each 48C at 2000 g for 10 min immediately after withdrawal group of rats with aortocaval shunt) for volume expansion, and the plasma was kept at 2808C until extraction. The hemodynamic and renal measurements and angiotensin blood was replaced with the same amount of blood from inhibition. A second set of experiments was performed donor animals (shunt-or sham-operated rats, respectively). C-terminal ANP plasma samples were extracted with C18 pressures were registered at baseline, during and after Sep-Pak columns, which had been equilibrated with acevolume expansion using a Statham P23XL transducer and tonitrile and ammonium acetate (0.2%, pH 4.0). After a Gould AMP 4600 amplifier. Heart rate was derived from loading of plasma, the columns were washed with amthe arterial blood pressure signal. monium acetate and ANP was eluted with acetonitrile (60%) and ammonium acetate (40%), following a previ-2.6. Angiotensin converting enzyme inhibition (ACEI) ously described protocol [24] . Samples were then meaand AT1-blockade sured by radioimmunoassay [24] which was performed with antibodies kindly provided by Dr. J. Gutkowska, Thirty days after shunt induction, the angiotensin conMontreal, Canada. Cardiac concentrations of ANP were verting enzyme was acutely inhibited with ramiprilat given diluted and directly determined by RIA in the supernatants intravenously (50 mg / kg, dissolved in 150 ml of NaHCO 3 which were kept at 2808C after RNA extraction with the 0.83%) immediately before the beginning of the baseline lithium chloride method [25] . Plasma samples for the period. As we aimed to analyze the effect of angiotensin N-terminal ANP (1-98) were directly determined by RIA inhibition without any decrease in blood pressure, the dose [26] . Prior to determination by radioimmunoassay, plasma of 50 mg / kg has been chosen following several publicGMP was extracted with alumina (AG7) and Dowex cations indicating that 1 mg / kg induced a sustained (AG50W-X8) columns, while urinary cGMP was deterhypotensive effect [30] and 50 mg / kg did not induce any mined directly using a specific radioimmunoassay [27] .
hemodynamic changes [31] . AT1 receptors were blocked Antibodies were donated by Dr. P. Hamet, Montreal, with valsartan (0.3 mg / kg, dissolved in 150 ml of Canada. For Ang II measurements, blood was collected in NaHCO 0.83%) intravenously. This dose had previously 3 prechilled Na-EDTA tubes (final concentration 7 mM) at been demonstrated to be without hypotensive effects [32] . baseline. O-phenantrolin (Merck, Darmstadt, Germany, Vehicle treated animals received the same amount of final concentration 1.25 mM) was added and Ang II was NaHCO 0.83%.
3 measured by radioimmunoassay as described previously in detail [28, 29] . Mean intra-assay variabilities were 11% and 2.7. RNA extraction and hybridization mean inter-assay variabilities were 15%. The cross-reactivity to Angiotensin I and other peptides was less than
In a second set of experiments, the hearts of sham-0.01% [28] . Hematocrit, which might have changed after operated controls and rats with aortocaval shunt were acute volume expansion, was not measured and the plasma excised 30 days after shunt production for RNA measurehormone concentrations could thus have been underestiments. RNA was extracted following the lithium-chloride mated.
method [25] . The supernatants were kept at 2808C for measurements of ANP tissue concentrations. For northern 2.5. Hemodynamic measurements blotting, 2 mg (atria) and 15 mg (ventricles) of spectrophotometrically determined total RNA was used. DenatuHemodynamic studies were performed under chloral ration was performed with glyoxal buffer (1 M glyoxal, hydrate anesthesia (400 mg / kg) 30 days after shunt 50% dimethylsulphoxide, 10 mM sodium dihydrogenphosproduction. A PE-50 tubing catheter was inserted via the phate, pH 7.0). The RNA was electrophoresed through a right jugular vein into the superior vena cava for measuredenaturating 1.2% agarose gel (4 h, 100 V) and transferred ments of central venous pressure. Arterial blood pressure to a 13 N Nylon membrane. An ANP specific cRNA probe was measured by cannulating the right carotid artery. Both was prepared from the prepro-ANP cDNA fragment which Hemodynamic measurements before acute volume expansion (Table 2) showed no significant differences in had been provided by Bloch and Seidman (Boston, MA, heart rate or mean arterial blood pressure between rats with USA) and was cloned in a pSP64 plasmid. ANP-mRNA aortocaval shunt and control rats. The right atrial pressure expression was compared to b-actin-mRNA expression, was significantly higher in rats with aortocaval shunt which was not different in the samples of rats with (5.962.2 mmHg) compared to control rats (3.060.6 aortocaval shunt and sham-operated controls. HybridizammHg, p,0.05). Treatment with an ACEI or AT1-antago-32 tion was performed with radioactive labeled P-UTP nist did not influence baseline hemodynamic variables. probes (100 mCi) in 50% formamide, 50 mM sodium Acute volume expansion induced a significant increase in phosphate (pH 6.8), 1 M NaCl, 200 mg / ml salmon sperm right atrial pressures in control rats as well as in rats with DNA, 5x Denhardt's solution, 0.1% SDS, and 10 mM aortocaval shunt treated with vehicle, ACEI and AT1-EDTA for 18 h at 658C. Filters were washed twice for 5
antagonist. No significant changes in mean arterial blood min with 1x SSC, 0.1% SDS at 658C and once with 0.1x pressure or heart rate occurred after acute volume expan-SSC and 0.1% SDS for 15 min at 658C. The filters were sion in any group. exposed for 24 h at 2708C for autoradiography and quantified with a laser densitometer.
Angiotensin II plasma levels
In rats with aortocaval shunt, Ang II plasma levels were 2.8. Statistical analysis significantly increased compared to sham-operated rats (360682 vs. 146617 pmol / l, p,0.05), indicating activaDifferences between groups were evaluated with the tion of the renin-angiotensin system. We had previously unpaired Student's t-test and the Wilcoxon rank sum test shown that plasma renin activity was increased in parallel where appropriate. The responses to acute volume expanin the aortocaval shunt model [33] . In the ACEI treated sion were compared using two-way analysis of variance group, the Ang II plasma concentrations decreased to with a posteriori comparison (Bonferroni). The signifi-116626 pmol / l ( p,0.01), whereas the AT1-antagonist increased Ang II plasma levels to 563619 pmol / l ( p, 0.05), which is consistent with previous reports [34] . Acute volume expansion did not significantly change Ang II levels in any group.
ANP release, diuretic and cGMP response after acute volume expansion
Baseline plasma levels of C-terminal ANP were elevated about 8-fold in rats with aortocaval shunt compared to sham-operated controls (380633 vs. 4763 pmol / l, p, 0.001, Fig. 2a ). While C-terminal ANP levels in control animals increased almost four-fold in response to acute volume expansion (from 4763 to 203612 pmol / l, p, 0.001), no significant increase could be observed in rats with aortocaval shunt. The lack of C-terminal ANP to respond to acute volume expansion in rats with aortocaval shunt was paralleled by unchanged N-terminal ANP plasma levels indicating a blunted cardiac release of the peptide (Fig. 2b) . Measurements of plasma concentrations of C-and N-terminal ANP at the end of the following 20 min periods (t2, t3, data not shown) demonstrated that the maximal increase in ANP plasma concentrations occurred at the end of t1, excluding a delayed increase in ANP plasma concentrations.
The baseline plasma concentrations of cGMP, a marker of the ANP-activated guanylate cyclase, were higher in rats with aortocaval shunt than in control rats (Fig. 2c, p Fig. 3a ) in rats with aortocaval shunt (from 26.863.5 to 43.463.1 pmol / min) compared to control rats (from 22.662.2 to 61.763.9 pmol / min). Baseline cGMP excretion (in contrast to urinary cGMP concentration) was not elevated in rats with aortocaval shunt, which might be due to the lower baseline diuresis observed in this model. The baseline diuresis in rats with aortocaval shunt was lower than in sham-operated control Treatments were ACE-inhibition (ACEI), AT1-antagonist (AT1), or vehicle. Data are presented as mean6SE, n58-12 in each group, *5p, 0.05, **5p,0.01 and ***5p,0.001 (vs. baseline).
ANP synthesis and content in atria and ventricles
We analyzed ANP synthesis and tissue content to exclude depleted cardiac stores as a cause for the blunted was significantly increased in rats with aortocaval shunt in release of ANP after acute volume expansion and deboth ventricles (Table 3) . Measurements of cardiac ANP termined the ANP-mRNA expression in atria and ventricontent indicated higher amounts in both atria and in the cles. b-actin-mRNA expression was analyzed to exclude a left ventricle. When expressed as ANP concentrations per nonspecific increase of mRNA synthesis. Fig. 4 shows a tissue weight, no significant changes between rats with typical Northern blot of ANP-mRNA and b-actin-mRNA aortocaval shunt and control rats were found. This apparent expression in left ventricles of rats with aortocaval shunt difference between ANP content and ANP concentration is and control rats. The ANP-mRNA to b-actin-mRNA ratio due to an increased cardiac weight in rats with aortocaval 
Effect of ACEI and AT1 blockade on ANP release and cGMP plasma levels
Having shown that the renin-angiotensin system was activated in rats with aortocaval shunt, we then analyzed whether its inhibition may be able to improve the blunted ANP release after acute volume expansion. Compared to vehicle treated rats, C-terminal ANP plasma levels were lower in rats treated with ACEI (Fig. 2a, 206636 vs. 379633 pmol / l with vehicle, p,0.01). After acute volume expansion, C-terminal ANP plasma levels increased significantly in rats treated with ACEI. The increase in ANP plasma concentrations after acute volume expansion, which was blunted in vehicle treated rats with aortocaval shunt, was completely restored with ACEI, compared to sham-operated rats. Similarly, the AT1-antagonist normalized the ANP release after volume expansion (Fig. 2a) . The increase in C-terminal ANP with ACEI was paralleled by a similar increase in N-terminal ANP levels (Fig. 2b) . These data indicate that a facilitated release, rather than a diminished degradation, was responsible for the rise in ANP plasma levels after acute volume expansion. While plasma cGMP after acute volume expansion did not change in vehicle treated rats with aortocaval shunt, ACEI as well as AT1 blockade induced a significant increase in plasma cGMP (Fig. 2c) after acute volume expansion. Thus, inhibition of the renin-angiotensin system by either ACEI or AT1-antagonists restored the blunted ANP release and cGMP response after acute volume expansion in rats with aortocaval shunt. right atrial pressure was blunted as indicated by an almost horizontal slope in the vehicle treated rats with aortocaval shunt (Table 1) . Thus, the blunted ANP release after shunt. Acute ACEI or AT1 blockade restored the ANP volume expansion does not seem to be due to either release per increase in right atrial pressure after volume diminished ANP synthesis or to depleted ANP stores. expansion resulting in a slope steeper than in vehicle treated rats. These data again indicate that inhibition of the sponse was significantly improved by ACEI ( p,0.001) renin-angiotensin system improved ANP release even and was not statistically different from the diuretic rewhen normalized per increase in right atrial pressure.
sponse measured in sham-operated animals. Similarly, the diuretic response after acute volume expansion could be 3.8. Effect of ACEI and AT1 blockade on renal improved with the AT1-antagonist. responses Fig. 3a shows the excretion of the second messenger 4. Discussion cGMP at baseline and after acute volume expansion compared to vehicle treated rats. Again, the blunted Our major new observation is the effect of ACEI and increase in cGMP excretion in rats with aortocaval shunt AT1 blockade on ANP release after acute volume expanwas restored by either inhibition of ACE or AT1 blockade.
sion. The renin-angiotensin system is activated in heart As shown in Fig. 3b , the diuresis at baseline more than failure, as reflected by increased Ang II levels in our study. doubled ( p,0.001), compared to vehicle treated rats with Aldosterone production as well as renin release are known aortocaval shunt. In parallel to the enhanced cGMP to be inhibited by ANP [17, 18] . Acute ACEI or AT1 excretion after acute volume expansion, the diuretic reblockade led to lower basal ANP plasma levels, which is consistent with previous studies [35] [36] [37] . The dosages of ACEI or AT1-antagonist used in our study did not induce any hemodynamic changes. The blunted C-terminal ANP increase after acute volume expansion was restored with ACEI. The parallel increase in N-terminal ANP plasma levels, as a more specific marker for endogenous ANP secretion [38] , supports the notion of a facilitated ANP release rather than an altered degradation. We showed that the diuretic response to acute volume expansion was blunted in rats with aortocaval shunt, an established model of moderate high-output heart failure [20] [21] [22] . The blunted diuretic response to acute volume expansion was at least partly due to a diminished ANP release. The atria are the most important source for ANP release in response to acute volume load [39] . Failure of ANP synthesis and depletion of cardiac stores could have explained the blunted ANP increase in response to acute volume expansion. We found that atrial ANP-mRNA expression was not decreased. In both ventricles, the ANPmRNA was significantly increased. We and others have Fig. 5 . The relationship between the increase of N-terminal ANP plasma described that atrial and ventricular ANP synthesis was concentrations and the rise in right atrial pressures (RAP) after acute volume expansion is depicted for control rats and rats with aortocaval markedly increased in heart failure rats and in the failing shunt treated with either vehicle, ACEI or AT1-antagonist. The blunted human heart [8] [9] [10] 40] . The ANP, which is released after N-terminal ANP increase in rats with aortocaval shunt treated with acute volume expansion, originates mainly from the atria vehicle was restored with ACEI and AT1-antagonist, although the [39, 41] . ANP contents were elevated in both atria and in changes in RAP were similar to vehicle treated rats with aortocaval shunt the left ventricle of rats with aortocaval shunt compared to and to control rats. Data are expressed as mean6SE, n58-12 in each group, *5p,0.05 (vs. vehicle treated rats with aortocaval shunt).
sham-operated controls. In the aortocaval shunt model, at Pennsylvania State University on February 23, 2013 http://cardiovascres.oxfordjournals.org/ Downloaded from atrial ANP was reported to show a tendency towards system. Our study was performed in anesthetized animals higher levels and ventricular ANP increased [42] , which is with chronic activation of the renin-angiotensin system. consistent with our observations. Our findings therefore Thus, we cannot exclude the possibility that a further suggest that depleted cardiac and atrial stores were not stimulated renin-angiotensin system might have contriburesponsible for the attenuated ANP release after acute ted to the results obtained. Analysis of renin transgenic rats volume expansion. ANP release in response to volume demonstrated a blunted ANP release in response to acute expansion depends on the atrial pressure and wall stress volume load [54] , indicating that genetic modification of [1, 43] . We observed a significant increase in right atrial the renin-angiotensin system influences the ANP release. pressures in rats with aortocaval shunt after acute volume These findings suggests that the effect of angiotensin, as expansion, which was not different from the increase in well as of ACEI and AT1-antagonists, might be different control rats. Therefore, neither depleted cardiac ANP in a state of a chronically activated angiotensin system. stores, nor a blunted elevation of atrial pressures could Consistent with this notion, ACEI restored the ANP explain the attenuated ANP release.
response to acute volume expansion in patients with ANP evokes the stimulation of the particulate guanylate cardiomyopathy [7] . Although not investigated in this cyclase and results in elevated cGMP levels in plasma and study, it is possible that various other mechanisms might increased urinary cGMP excretion [11, 12, 15] . In the be involved in the release of natriuretic peptides [55] and present study, the ANP release in response to acute volume the relative contribution of endocrine (angiotensin, endoexpansion was followed by an increase in plasma and thelin) and mechanical factors [55] may be different in the urinary cGMP in control rats. In rats with aortocaval shunt, healthy state compared to heart failure. In particular, it is however, the diuretic response to acute volume expansion intriguing to speculate on the effect of ET-1 and endothelin was reduced to about one third of the control values. The receptor blockade on ANP release in the normal and heart ANP release was blunted and consequently, the increase in failure animals. urinary cGMP excretion was diminished and plasma
We observed a restored ANP release under acute cGMP did not increase. The diminished release of ANP is inhibition of the renin-angiotensin system. We did not therefore likely to be a cause for the blunted renal response investigate the mechanism by which Ang II modulates the to acute volume expansion.
ANP release. A possible direct interaction between Ang II The increase in ANP plasma levels after acute volume and ANP release at the cellular level in the heart is expansion was restored by acute inhibition of the reninintriguing. However, we did not demonstrate that the angiotensin system via ACEI or AT1 blockade indicating a interaction between both humoral systems occurs directly novel interaction between these two humoral systems. The on the cardiomyocytes. observation that ACEI restores the blunted ANP release in To assess the biological importance of the restored ANP rats with aortocaval shunt appears to contradict earlier release, we measured diuresis and cGMP excretion during studies, which reported that the ANP release was stimu-ACEI and AT1 blockade. We had previously shown that lated by Ang II in neonatal cardiomyocytes [44] . In the basal diuresis and the diuretic response to acute volume superfused isolated atria, the reports are contradictory load was diminished in rats with an aortocaval shunt, [45, 46] . In isolated perfused hearts, Ang II induced ANP compared to control rats [33] . The basal diuresis was release along with elevated ventricular pressures [47] .
increased with ACEI, even though ANP values were lower Since these studies were performed in isolated cells and compared to vehicle treated rats. The lack of statistical organs, it may not be possible to transpose them to intact effect on baseline diuresis with the AT1-antagonist could animals or humans. Several studies analyzed Ang II effects be due to a dose, which might not have been equipotent to in vivo and described increased ANP plasma levels in rats the ACEI. The ACEI effect may be explained by the [46, 48] and men [49, 50] . However, systolic blood pressure contribution of bradykinin, which is known to increase increased in parallel in these studies [46, 48, 49] and a after ACEI. In contrast to the baseline diuresis and similar ANP release was achieved with other pressor natriuresis, the response to acute volume expansion was agents as well [50] . When the blood pressure effect of Ang most likely ANP dependent. We observed that the restored II was blocked [51], or when a nonpressor dose of Ang II ANP release resulted in improved renal excretory rewas infused [46], no effect on basal ANP plasma consponses. The second messenger cGMP increased in plascentrations could be observed. These observations suggest ma. Increased plasma cGMP concentrations have been that the effect of Ang II on the ANP release might have reported to be induced by ANP via a stimulation of been obscured by its vasoconstricting and hypertensive particulate guanylate cyclase [56] , but not by nitric oxideaction. stimulated soluble guanylate cyclase. Furthermore, the Previous authors had blocked the renin-angiotensin renal excretion of cGMP was enhanced. These findings system with ACEI or AT1-antagonists and had failed to suggest that the restored renal excretory response to observe any effect on ANP release [52, 53] . However, these volume expansion is mediated at least in part by the studies were performed in conscious and healthy rats reestablished ANP release. We previously demonstrated without any previous activation of the renin-angiotensin that inhibition of the neutral endopeptidase, the ANP 
